Literature DB >> 31737208

Long noncoding RNA DLX6-AS1 targets miR-124-3p/CDK4 to accelerate Ewing's sarcoma.

Xiaomei Lei1, Siping Yang2, Yuanyuan Yang1, Juan Zhang3, Yue Wang1, Minhui Cao4.   

Abstract

Ewing's sarcoma is one of leading cause of malignancy occurred in the children and adolescents worldwide. Given the emerging critical role of long noncoding RNA (lncRNA) in the human cancer, as well as Ewing's sarcoma, we aim to identify the biological role of DLX6-AS1 in the tumorigenesis. Results unveil that DLX6-AS1 expression was increased in the tissue sample and cells. Functionally, the silencing of DLX6-AS1 could repress the proliferation and accelerate the apoptosis of Ewing's sarcoma cells. Mechanically, DLX6-AS1 functioned as the sponge of miR-124-3p, and then miR-124-3p targeted the 3'-UTR of CDK4 mRNA, forming the DLX6-AS1/miR-124-3p/CDK4 regulatory pathway. In conclusion, the critical role of DLX6-AS1 might unveil a potential therapeutic target for Ewing's sarcoma. AJTR
Copyright © 2019.

Entities:  

Keywords:  CDK4; DLX6-AS1; Ewing’s sarcoma; miR-124-3p

Year:  2019        PMID: 31737208      PMCID: PMC6834508     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  32 in total

1.  A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.

Authors:  Lillian M Guenther; Neekesh V Dharia; Linda Ross; Amy Conway; Amanda L Robichaud; Jerrel L Catlett; Caroline S Wechsler; Elizabeth S Frank; Amy Goodale; Alanna J Church; Yuen-Yi Tseng; Rajarshi Guha; Crystal G McKnight; Katherine A Janeway; Jesse S Boehm; Jaume Mora; Mindy I Davis; Gabriela Alexe; Federica Piccioni; Kimberly Stegmaier
Journal:  Clin Cancer Res       Date:  2018-11-05       Impact factor: 12.531

2.  Prognostic factors for survival in Ewing sarcoma: A systematic review.

Authors:  S E Bosma; O Ayu; M Fiocco; H Gelderblom; P D S Dijkstra
Journal:  Surg Oncol       Date:  2018-07-30       Impact factor: 3.279

3.  Long non-coding RNA DLX6-AS1 aggravates hepatocellular carcinoma carcinogenesis by modulating miR-203a/MMP-2 pathway.

Authors:  Lei Zhang; Xiaowei He; Ting Jin; Li Gang; Zhenlin Jin
Journal:  Biomed Pharmacother       Date:  2017-11-06       Impact factor: 6.529

4.  Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.

Authors:  Michelle Marques Howarth; David Simpson; Siu P Ngok; Bethsaida Nieves; Ron Chen; Zurab Siprashvili; Dedeepya Vaka; Marcus R Breese; Brian D Crompton; Gabriela Alexe; Doug S Hawkins; Damon Jacobson; Alayne L Brunner; Robert West; Jaume Mora; Kimberly Stegmaier; Paul Khavari; E Alejandro Sweet-Cordero
Journal:  J Clin Invest       Date:  2014-11-17       Impact factor: 14.808

5.  Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.

Authors:  Yongjie Huang; Ran Ni; Jing Wang; Ying Liu
Journal:  Biomed Pharmacother       Date:  2018-11-26       Impact factor: 6.529

6.  LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling.

Authors:  Rong-Mou Zhang; Ting Tang; Hai-Ming Yu; Xue-Dong Yao
Journal:  Biochem Biophys Res Commun       Date:  2018-11-13       Impact factor: 3.575

Review 7.  SNHG20: A vital lncRNA in multiple human cancers.

Authors:  Wei Zhao; Xiaozhou Ma; Lina Liu; Qingyu Chen; Zihao Liu; Zheng Zhang; Shiqing Ma; Zhonghou Wang; Hongfa Li; Zuomin Wang; Jie Wu
Journal:  J Cell Physiol       Date:  2019-01-15       Impact factor: 6.384

Review 8.  Relations between approved platinum drugs and non-coding RNAs in mesothelioma.

Authors:  Bernhard Biersack
Journal:  Noncoding RNA Res       Date:  2018-08-30

9.  Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.

Authors:  Takashi Murakami; Arun S Singh; Tasuku Kiyuna; Sarah M Dry; Yunfeng Li; Aaron W James; Kentaro Igarashi; Kei Kawaguchi; Jonathan C DeLong; Yong Zhang; Yukihiko Hiroshima; Tara Russell; Mark A Eckardt; Jane Yanagawa; Noah Federman; Ryusei Matsuyama; Takashi Chishima; Kuniya Tanaka; Michael Bouvet; Itaru Endo; Fritz C Eilber; Robert M Hoffman
Journal:  Oncotarget       Date:  2016-07-26

10.  LncRNA-PCAT1 targeting miR-145-5p promotes TLR4-associated osteogenic differentiation of adipose-derived stem cells.

Authors:  Lingjia Yu; Hao Qu; Yifeng Yu; Wenjing Li; Yu Zhao; Guixing Qiu
Journal:  J Cell Mol Med       Date:  2018-10-19       Impact factor: 5.310

View more
  8 in total

Review 1.  Promising long noncoding RNA DLX6-AS1 in malignant tumors.

Authors:  Chen Xue; Longxian Lv; Jiangwen Jiang; Lanjuan Li
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

Review 2.  Strategies of LncRNA DLX6-AS1 on Study and Therapeutics.

Authors:  Yanyan Zhao; Pei Li
Journal:  Front Genet       Date:  2022-06-01       Impact factor: 4.772

Review 3.  Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis.

Authors:  Dave N T Aryee; Valerie Fock; Utkarsh Kapoor; Branka Radic-Sarikas; Heinrich Kovar
Journal:  Cells       Date:  2022-04-08       Impact factor: 7.666

Review 4.  A review on the role of cyclin dependent kinases in cancers.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Peixin Dong; Nikolaus Gassler; Mohammad Taheri; Aria Baniahmad; Nader Akbari Dilmaghani
Journal:  Cancer Cell Int       Date:  2022-10-20       Impact factor: 6.429

Review 5.  The Landscape of Regulatory Noncoding RNAs in Ewing's Sarcoma.

Authors:  Connor Barrett; Anuj Budhiraja; Vijay Parashar; Mona Batish
Journal:  Biomedicines       Date:  2021-07-31

6.  Upregulated lncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10 axis.

Authors:  Xiaoming Liu; Dandan Peng; Yixin Cao; Yuanzhe Zhu; Jianjun Yin; Guangxing Zhang; Xiaodong Peng; Yanqiu Meng
Journal:  Cancer Gene Ther       Date:  2020-12-04       Impact factor: 5.987

Review 7.  DLX6-AS1: A Long Non-coding RNA With Oncogenic Features.

Authors:  Soudeh Ghafouri-Fard; Sajad Najafi; Bashdar Mahmud Hussen; Aryan R Ganjo; Mohammad Taheri; Mohammad Samadian
Journal:  Front Cell Dev Biol       Date:  2022-02-25

8.  ELFN1-AS1 accelerates cell proliferation, invasion and migration via regulating miR-497-3p/CLDN4 axis in ovarian cancer.

Authors:  Youkun Jie; Lu Ye; He Chen; Xiaohong Yu; Li Cai; Wenfeng He; Yonghui Fu
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.